Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.62 |
| ▸ | KDR | P35968 | 9/20 | 0.53 |
| ▸ | TEK | Q02763 | 7/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937617 | 0.80 | KDR (0.69) | BRAFKDRTEK | |
| SCHEMBL5899289 | 0.79 | BRAF (0.57) | BRAFKDRTEKPDGFRB | |
| SCHEMBL1662296 | 0.77 | RAF1 (0.64) | BRAFKDRTEK | |
| SCHEMBL5899257 | 0.75 | BRAF (0.58) | BRAFKDRTEK | |
| SCHEMBL19888735 | 0.75 | KDR (0.63) | BRAFKDRTEK | |
| SCHEMBL5767425 | 0.74 | BRAF (0.59) | BRAFKDRTEK | |
| SCHEMBL1660411 | 0.74 | RAF1 (0.80) | BRAFKDRTEKEPHB4PDGFRB | |
| SCHEMBL5351020 | 0.73 | BRAF (0.58) | BRAFKDRTEKP2RY1 | |
| SCHEMBL31504025 | 0.73 | KDR (0.64) | BRAFKDRTEK | |
| SCHEMBL17360410 | 0.73 | NTRK1 (0.81) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | TIE1, UCK2, UTS2R | BRAF 34/4885KDR 45/4885TEK 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.